American Society of Hematology

Figure 2.

$Figure 2. Imetelstat treatment leads to depletion of malignant HPCs. The absolute number of total JAK2V617F+ and homozygous JAK2V617F+ CFU-GM was calculated by multiplying the total number of CFU-GM by the fraction of JAK2V617F+ or homozygous JAK2V617F+ CFU-GM (Table 1) generated in cultures of JAK2V617F+ splenic or PB MF CD34+ cells treated with cytokines alone or cytokines plus MM or Ime (7.5 μM) for 7 days. The percentage of the absolute number of total JAK2V617F+ and homozygous JAK2V617F+ CFU-GM generated in cultures of treated with cytokines plus Ime relative to that generated in cultures treated with cytokines plus MM is shown. n = 4. &P = .08, *P = .03.$

Imetelstat treatment leads to depletion of malignant HPCs. The absolute number of total JAK2V617F⁺ and homozygous JAK2V617F⁺ CFU-GM was calculated by multiplying the total number of CFU-GM by the fraction of JAK2V617F⁺ or homozygous JAK2V617F⁺ CFU-GM (Table 1) generated in cultures of JAK2V617F⁺ splenic or PB MF CD34⁺ cells treated with cytokines alone or cytokines plus MM or Ime (7.5 μM) for 7 days. The percentage of the absolute number of total JAK2V617F⁺ and homozygous JAK2V617F⁺ CFU-GM generated in cultures of treated with cytokines plus Ime relative to that generated in cultures treated with cytokines plus MM is shown. n = 4. ^&P = .08, *P = .03.

This Feature Is Available To Subscribers Only